Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy.

Published on Aug 2, 2017in European Urology17.947
· DOI :10.1016/J.EURURO.2017.07.026
Nicola Fossati36
Estimated H-index: 36
(UniSR: Vita-Salute San Raffaele University),
R. Jeffrey Karnes70
Estimated H-index: 70
(Mayo Clinic)
+ 21 AuthorsAlberto Briganti96
Estimated H-index: 96
(UniSR: Vita-Salute San Raffaele University)
Sources
Abstract
Abstract Background Salvage radiation therapy (SRT) is a recommended treatment option for biochemical recurrence after radical prostatectomy (RP). However, its effectiveness may be limited to specific categories of patients. Objective We aimed to identify the optimal candidates for early SRT after RP. Design, setting, and participants The study included 925 node-negative patients treated with SRT after RP at seven institutions. Patients received SRT for either prostate-specific antigen (PSA) rising, or PSA persistence after RP that was defined as PSA level ≥0.1 ng/ml at 1 mo after surgery. All patients received local radiation to the prostate and seminal vesicle bed. Outcome measurements and statistical analysis The primary outcome measured was distant metastasis after SRT. Regression tree analysis was used to develop a risk-stratification tool. Multivariable Cox regression analysis and nonparametric curve fitting methods were used to explore the relationship between PSA level at SRT and the probability of metastasis-free survival at 8 yr. Results and limitations At a median follow-up of 8.0 yr, 130 patients developed distant metastasis. At multivariable analysis, pre-SRT PSA level was significantly associated with distant metastasis (hazard ratio: 1.06, p Conclusions We developed an accurate risk stratification tool to facilitate the individualised recommendation for early SRT based on prostate cancer characteristics. Early SRT proved to be beneficial only in selected groups of patients who are more likely to be affected by clinically significant but not yet systemic recurrence at the time of salvage treatment administration. Patient summary In patients affected by prostate cancer recurrence after radical prostatectomy, the early administration of salvage radiation therapy is beneficial only for selected subgroups of patients. In this study, these groups of patients were identified.
📖 Papers frequently viewed together
315 Citations
177 Citations
References33
Newest
#1Giorgio Gandaglia (UniSR: Vita-Salute San Raffaele University)H-Index: 10
#2Stephen A. Boorjian (Mayo Clinic)H-Index: 80
Last. Alberto Briganti (UniSR: Vita-Salute San Raffaele University)H-Index: 10
view all 11 authors...
Abstract Background Prostate cancer (PCa) patients with prostate-specific antigen (PSA) persistence after radical prostatectomy (RP) are at increased risk of mortality, although the natural history of these men is heterogeneous and the optimal management has not been established. Objective To develop a model to predict cancer-specific mortality (CSM) and to test the impact of radiotherapy (RT) on survival in this setting. Design, setting, and participants We identified 496 patients treated with ...
15 CitationsSource
#1Nicola Fossati (UniSR: Vita-Salute San Raffaele University)H-Index: 36
#2R. Jeffrey Karnes (Mayo Clinic)H-Index: 70
Last. Alberto Briganti (UniSR: Vita-Salute San Raffaele University)H-Index: 96
view all 24 authors...
Abstract Background Three prospective randomised trials reported discordant findings regarding the impact of adjuvant radiation therapy (aRT) versus observation for metastasis-free survival (MFS) and overall survival (OS) among patients with pT3N0 prostate cancer treated with radical prostatectomy (RP). None of these trials systematically included patients who underwent early salvage radiation therapy (esRT). Objective To test the hypothesis that aRT was associated with better cancer control and...
64 CitationsSource
#1Nicolas MottetH-Index: 40
#2Joaquim Bellmunt (Harvard University)H-Index: 87
Last. Philip CornfordH-Index: 27
view all 22 authors...
Abstract Objective To present a summary of the 2016 version of the European Association of Urology (EAU) - European Society for Radiotherapy & Oncology (ESTRO) - International Society of Geriatric Oncology (SIOG) Guidelines on screening, diagnosis, and local treatment with curative intent of clinically localised prostate cancer (PCa). Evidence acquisition The working panel performed a literature review of the new data (2013–2015). The guidelines were updated and the levels of evidence and/or gra...
1,998 CitationsSource
#1Philip CornfordH-Index: 27
#2Joaquim Bellmunt (Harvard University)H-Index: 87
Last. Nicolas MottetH-Index: 40
view all 15 authors...
Abstract Objective To present a summary of the 2016 version of the European Association of Urology (EAU) – European Society for Radiotherapy & Oncology (ESTRO) – International Society of Geriatric Oncology (SIOG) Guidelines on the treatment of relapsing, metastatic, and castration-resistant prostate cancer (CRPC). Evidence acquisition The working panel performed a literature review of the new data (2013–2015). The guidelines were updated, and the levels of evidence and/or grades of recommendatio...
856 CitationsSource
#1Emanuele Zaffuto (UdeM: Université de Montréal)H-Index: 16
#2Giorgio Gandaglia (UniSR: Vita-Salute San Raffaele University)H-Index: 47
Last. Alberto Briganti (UniSR: Vita-Salute San Raffaele University)H-Index: 96
view all 13 authors...
Purpose: The effect of time between radical prostatectomy and radiation therapy on postoperative functional outcomes is still unclear in patients with surgically managed prostate cancer. We hypothesized that a shorter time between radical prostatectomy and radiotherapy might be associated with worse functional recovery rates after radical prostatectomy.Materials and Methods: We retrospectively evaluated 2,190 patients treated with radical prostatectomy and stratified according to radiotherapy sc...
40 CitationsSource
#1Ahmed E. Abugharib (UM: University of Michigan)H-Index: 6
#2William C. Jackson (UM: University of Michigan)H-Index: 16
Last. Daniel E. Spratt (UM: University of Michigan)H-Index: 50
view all 13 authors...
Purpose: Early salvage radiotherapy following radical prostatectomy for prostate cancer is commonly advocated in place of adjuvant radiotherapy. We aimed to determine the optimal definition of early salvage radiotherapy.Materials and Methods: We performed a multi-institutional retrospective study of 657 men who underwent salvage radiotherapy between 1986 and 2013. Two comparisons were made to determine the optimal definition of early salvage radiotherapy, including 1) the time from radical prost...
57 CitationsSource
#1Thomas Seisen (Vattikuti Urology Institute)H-Index: 25
#2Quoc-Dien Trinh (Brigham and Women's Hospital)H-Index: 68
Last. Firas Abdollah (Vattikuti Urology Institute)H-Index: 64
view all 3 authors...
Early use of salvage radiotherapy in patients with prostate cancer with biochemical recurrence after radical prostatectomy has consistently been shown to provide better oncological outcomes than late use. However, the corresponding scientific literature might be subject to lead-time bias, given that in virtually all the available comparative studies, investigators calculated the survival period of included patients from the time of salvage radiotherapy — instead of from the time of radical prost...
9 CitationsSource
#1William U. Shipley (Harvard University)H-Index: 100
#2W. SeiferheldH-Index: 18
Last. Howard M. SandlerH-Index: 96
view all 22 authors...
BackgroundSalvage radiation therapy is often necessary in men who have undergone radical prostatectomy and have evidence of prostate-cancer recurrence signaled by a persistently or recurrently elevated prostate-specific antigen (PSA) level. Whether antiandrogen therapy with radiation therapy will further improve cancer control and prolong overall survival is unknown. MethodsIn a double-blind, placebo-controlled trial conducted from 1998 through 2003, we assigned 760 eligible patients who had und...
315 CitationsSource
#1Rahul D. Tendulkar (Cleveland Clinic)H-Index: 21
#2Shree Agrawal (Case Western Reserve University)H-Index: 7
Last. Andrew J. Stephenson (Case Western Reserve University)H-Index: 57
view all 20 authors...
PurposeWe aimed to update a previously published, multi-institutional nomogram of outcomes for salvage radiotherapy (SRT) following radical prostatectomy (RP) for prostate cancer, including patients treated in the contemporary era.MethodsIndividual data from node-negative patients with a detectable post-RP prostate-specific antigen (PSA) treated with SRT with or without concurrent androgen-deprivation therapy (ADT) were obtained from 10 academic institutions. Freedom from biochemical failure (FF...
177 CitationsSource
#1Bradley J. Stish (Mayo Clinic)H-Index: 10
#2Thomas M. Pisansky (Mayo Clinic)H-Index: 60
Last. Steven J. Buskirk (Mayo Clinic)H-Index: 30
view all 7 authors...
PurposeTo describe outcomes of salvage radiotherapy (SRT) for men with detectable prostate-specific antigen (PSA) after radical prostatectomy for prostate cancer and identify associations with outcomes.Patients and MethodsA total of 1,106 patients received SRT between January 1987 and July 2013, with median follow-up 8.9 years. Outcomes were estimated using Kaplan-Meier for overall survival (OS) and cumulative incidence for biochemical recurrence (BcR), distant metastases (DM), and cause-specifi...
118 CitationsSource
Cited By41
Newest
#1Nicholas G. Zaorsky (Penn State Cancer Institute)H-Index: 28
#2Jeremie Calais (UCLA: University of California, Los Angeles)H-Index: 20
Last. Amar U. Kishan (UCLA: University of California, Los Angeles)H-Index: 19
view all 7 authors...
More than 40% of men with intermediate-risk or high-risk prostate cancer will experience a biochemical recurrence after radical prostatectomy. Clinical guidelines for the management of these patients largely focus on the use of salvage radiotherapy with or without systemic therapy. However, not all patients with biochemical recurrence will go on to develop metastases or die from their disease. The optimal pre-salvage therapy investigational workup for patients who experience biochemical recurren...
Source
#1Peter E. Lonergan (UCSF: University of California, San Francisco)H-Index: 12
#2Janet E. Cowan (UCSF: University of California, San Francisco)H-Index: 43
Last. Peter R. Carroll (UCSF: University of California, San Francisco)H-Index: 141
view all 6 authors...
Background null A detectable prostate-specific antigen (PSA) following radical prostatectomy (RP) is an unfavorable prognostic factor. However, not all men with a detectable PSA experience recurrence. We describe the natural history and outcomes in men with a detectable PSA following RP in a contemporary cohort. null Methods null A retrospective analysis of men who underwent RP for non-metastatic prostate cancer at the University of California, San Francisco from 2000 to 2020 was performed. A de...
Source
#1Fabio ZattoniH-Index: 16
#2Isabel HeideggerH-Index: 21
Last. Massimo ValerioH-Index: 22
view all 15 authors...
Source
#1Elio MazzoneH-Index: 11
#2Paolo Dell'OglioH-Index: 28
Last. Alexandre MottrieH-Index: 34
view all 16 authors...
Abstract Background The feasibility and efficacy of robot-assisted radical prostatectomy (RARP) in locally advanced prostate cancer (PCa) patients with iT3 lesion at magnetic resonance imaging (MRI) are currently not explored. Objective To describe our revised RARP technique (ie, superextended RARP [SE-RARP]) for PCa patients with posterior iT3a or iT3b at MRI. Design, setting, and participants Data from 89 patients with posterior iT3a or T3b disease who underwent SE-RARP at a single high-volume...
1 CitationsSource
#1Dennie Meijer (VUmc: VU University Medical Center)H-Index: 1
#1D. Meijer (VUmc: VU University Medical Center)H-Index: 1
Last. André N. Vis (VUmc: VU University Medical Center)H-Index: 8
view all 10 authors...
Since the introduction of radiolabeled prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT), the ability to visualize recurrent prostate cancer has improved substantially. However, the diagnostic accuracy of radiolabeled PSMA PET/CT in patients with biochemical persistence (BCP; i.e., persistently measurable prostate-specific antigen (PSA)-values after robot-assisted laparoscopic radical prostatectomy (RARP)) is largely lacking. Therefore, the aim o...
1 CitationsSource
#1Ian Alberts (University of Bern)H-Index: 10
#2Robert Seifert (DKFZ: German Cancer Research Center)
Last. Ali Afshar-Oromieh (University of Bern)H-Index: 37
view all 4 authors...
Prostate-specific membrane antigen-PET/computed tomography (PSMA-PET/CT) is the investigation of choice for imaging prostate cancer. Demonstrating high diagnostic accuracy, PSMA-PET/CT detects disease at very early stages of recurrence, where the chances of a definitive cure may be at their greatest. A number of PSMA-radioligands are in established clinical routine, and there are currently only limited data and no single tracer can clearly be advocated over the others at present. Further clinica...
Source
#1Young Suk Kwon (RU: Rutgers University)H-Index: 9
#2Wei Wang (RU: Rutgers University)H-Index: 2
Last. Isaac Yi Kim (RU: Rutgers University)H-Index: 36
view all 8 authors...
Abstract Background We aimed to illustrate national trends of post-radical prostatectomy (RP) radiotherapy (RT) and compare outcomes and toxicities in patients receiving eRT versus observation with or without late radiotherapy (lRT). Methods Utilizing the Surveillance, Epidemiology, and End Results (SEER)-Medicare data from 2001 to 2011, we identified 7557 patients with high-risk pathologic features after RP (≥pT3N0 and/or positive surgical margins). Our study cohort consisted of patients receiv...
Source
#1Daimantas MilonasH-Index: 8
#2Z. VenclovasH-Index: 3
Last. Tomas RuzgasH-Index: 4
view all 4 authors...
OBJECTIVE To assess the significance of prostate-specific antigen (PSA) persistence at the first measurement after radical prostatectomy (RP) on long-term outcomes in different prostate cancer risk groups. METHODS Persistent PSA was defined as ≥0.1 ng/mL at 4-8 weeks after RP. Patients were stratified into low-, intermediate- and high-risk groups, according to the preoperative PSA, pathological stage, grade group and lymph nodes status. The ten-year cumulative incidence of biochemical recurrence...
Source
#1Jure Murgic (University of Zagreb)H-Index: 8
#2Blanka Jakšić (University of Zagreb)H-Index: 4
Last. Ana Fröbe (University of Zagreb)H-Index: 5
view all 16 authors...
Background Hypofractionated post-prostatectomy radiotherapy is emerging practice, however with no randomized evidence so far to support it's use. Additionally, patients with persistent PSA after prostatectomy may have aggressive disease and respond less well on standard salvage treatment. Herein we report outcomes for conventionally fractionated (CFR) and hypofractionated radiotherapy (HFR) in patients with persistent postprostatectomy PSA who received salvage radiotherapy to prostate bed. Metho...
Source
#1Alexander L Nesbitt (Griffith University)H-Index: 3
#2Philip G Smith (JCU: James Cook University)H-Index: 1
Last. Simon W Pridgeon (JCU: James Cook University)H-Index: 2
view all 5 authors...
Objective:This study aimed to analyse a population of men undergoing radical prostatectomy to determine whether a delay to surgery is associated with poorer outcomes. A secondary aim was to analyse...
1 CitationsSource